Work

A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.e15613

Authors: Anne M. Noonan, Saira Farid, Patrick Schnell, Danielle Trunzo, Pannaga G. Malalur, Ning Jin, Ashish Manne, Laith I. Abushahin, Shafia Rahman, John L. Hays, Rifat T. Elkhatib, Arjun Mittra, Sameek Roychowdhury, Maryam B. Lustberg, Alex Sparreboom, Shuiying Hu

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Yale University

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379336777

Cites:

Cited by:

Related to: 10